Please login to the form below
ERT
This page shows the latest ERT news and features for those working in and with pharma, biotech and healthcare.
European Commission approves potential new treatment for Pompe disease
muscles. Nexviadyme is an enzyme replacement therapy (ERT) and is currently the first and only newly approved medicine for Pompe disease in Europe in over 15 years. ... Nexviadyme is specifically designed to target the mannose-6-phosphate (M6P) receptor,
Latest news
-
Trial dents confidence in Sangamo’s gene-editing tech
Patients in the study are still being treated with Shire’s Elaprase (idursulfase), a recombinant form of IDS used as enzyme replacement therapy (ERT) in MPS II, and Macrae said: “we ... will need to wait and see how the high-dose cohort fares when
-
Sangamo’s first gene-editing trial doesn’t convince investors
these changes by conducting a controlled withdrawal of…ERT in patients enrolled in the study soon.”. ... Withdrawal from weekly ERT infusions would be “a very meaningful outcome” for patients with MPS II, he added.
-
Merck’s Brexit contingency plan? Stockpile medicines
AZ is part of the European Round Table of Industrialists (ERT) which met with Theresa May last month and warned that “the uninterrupted flow of goods is essential to both the
-
Foundry3 set sights on tailored patient support programmes
Agency partners with ERT to improve health outcomes. Hoping to bolster its patient support offering through the use of adaptive digital initiatives, Foundry. ... 3. , a creative, science and innovation agency has teamed up with data and tech group ERT.
-
First patient treated with Sangamo’s gene-editing tech
Even with regular infusions of ERT, which has markedly improved functional health outcomes, patients endure progressive damage to heart, bones, and lungs,” said Harmatz.
More from news
Approximately 1 fully matching, plus 10 partially matching documents found.
Latest Intelligence
-
Rare diseases: not so rare after all
Identification of the specific enzyme involved, which is either defective or absent, has led to the development of a first-generation treatment option: enzyme replacement therapy (ERT). ... ERT provides the patient with the recombinantly produced missing
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Almac Group appoints two new vice presidents
Prior to this, he spent over 12 years at ERT, a supplier of cardiac safety, respiratory and eCOA solutions, where her served in a series of management positions globally.
-
CRF Health boosts leadership team
He was most recently chief commercial officer at Greenphire, a clinical payment technology firm, and prior to that worked in the same role at eResearch Technology (ERT).
-
Fred Powell joins Celator as chief financial officer
Powell also held senior finance and administration positions at Eximias Pharmaceutical Corporation, Innaphase Corporation, and ERT (formerly EResearch Technology).
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Are you using Patient-Reported Outcomes (PROs) in your oncology trials? If not, why not?
The blog then went on to discuss the findings of a preference study implemented by ERT (a global healthcare company) designed to establish where patients prefer to complete their PROs (at
-
Making good practice common practice in rare disease
symptoms. Literature suggests fatigue may be the first symptom to significantly improve with enzyme replacement therapy (ERT), a key treatment for Gaucher Disease, but this critical factor may be overlooked when
-
ERT, Inc.
ERT is passionate and committed about transforming the way you conduct your drug development and healthcare efforts.
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Italy accelerates the path towards digital therapeutics implementation
- AstraZeneca’s mild combination asthma reliever approved in UK
- Bristol Myers Squibb’s Sotyktu approved by EC for plaque psoriasis
- Positive results for Almirall’s lebrikizumab in atopic dermatitis published in NEJM and BJD
- When to call in the specialists: strategy in Medical Affairs
- Time to talk about health inequalities
- Powering Rapid Cognitive Analysis with AI
- AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Ketchum appoints Conor Nash as global chief financial officer and chief operating officer
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
PMHub
Wilmington Healthcare
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...
Latest intelligence
- Time to talk about health inequalities
- Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
